Hypocomplementemia as a Risk Factor for Organ Damage Accrual in Patients with Systemic Lupus Erythematosus
Table 2
Comparisons of disease activity measures between SLE patient with normal (NC) and low complement levels (HC).
NC ()
HC ()
value
WAcS
1.2 (0.65, 3.22)
1.9 (0.9, 3.3)
0.91
Clinical SLEDAI max
8.0 (4.0, 12.0)
13.0 (9.0, 17.0)
<0.001
Mild flares (%)
33 (100)
69 (100)
—
Severe flares (%)
24 (72.7)
65 (94.2)
<0.001
Mild flares per annum
0.8 (0.4, 1.7)
1.1 (0.5, 1.85)
0.12
Severe flares per annum
0.2 (0, 0.5)
0.3 (0.1, 0.8)
0.010
Manifestation
Convulsions
0 (0)
10 (14.5)
0.02
Psychosis
0 (0)
3 (4.3)
0.22
Retinal
1 (3)
1 (1.4)
0.59
Cranial nerve
1 (3)
6 (8.7)
0.31
Vasculitis
6 (18.2)
24 (34.8)
0.07
Cylindruria
4 (12.1)
19 (27.5)
0.06
Proteinuria
6 (18.2)
34 (49.3)
<0.001
Arthritis
25 (75.8)
48 (69.6)
0.346
Rash
19 (5.6)
59 (85.5)
0.002
Alopecia
12 (3.4)
43 (62.3)
0.014
Ulcers
8 (24.2)
36 (52.2)
0.008
Serositis
5 (12.1)
25 (23.2)
0.16
Fevers
6 (18.2)
31 (44.9)
0.008
Hemolysis
2 (6.1)
4 (5.8)
0.98
Thrombocytopenia
4 (12.1)
25 (36.2)
0.012
Leucopenia
6 (18.2)
32 (46.4)
0.003
Thrombosis
4 (12.1)
8 (11.6)
0.89
Obstetric APS
4 (12.1)
12 (17.4)
0.49
Figures indicate median with interquartile range or numbers (%). WAcS: weighted average clinical SLEDAI score (see Methods). Clinical SLEDAI max: highest cSLEDAI score observed during the disease course; APS: antiphospholipid syndrome.
